

碳青霉烯类抗生素多立培南的研究进展

Research advances of carbapenems antibiotics doripenem

陆人杰;唐风雷;王燕龙;朱珊梅;徐军英;蒋星;

摘要:

多立培南是目前新型注射用碳青霉烯类抗生素,能有效治疗严重细菌感染。它对革兰阳性菌和革兰阴性菌,包括产超广谱 β 内酰胺酶菌株和厌氧菌抗菌作用显著。美国现已批准本品治疗成人复杂性腹腔内感染和复杂性尿路感染,包括肾盂肾炎。本文对多立培南的作用机制、临床研究进展以及安全性等进行综述。

关键词: 多立培南;碳青霉烯类;抗菌药;药物治疗法

基金项目:

通讯作者: 陆人杰;

Email:

参考文献:

- [1]KANIGA K,FLAMM R,TONG SY,et al.Worldwide experience with the use of doripenem against extended-spectrum- β -lactamase-producing and ciprofloxacin-resistant Enterobacteria-ceae:analysis of six phase 3 clinical studies[J].Antimicrob Agents Chemother,2010,54(5):2119-2124.
- [2]FUJIMURA T,KIMURA Y,YOSHIDA I,et al.In vitro antibacterial activity of doripenem,a novel parenteral carba-penem[J].Jpn J Chemother,2005,53(S-1):57-70.
- [3]MUSHTAQ S,GE Y,LIVERMORE DM.Comparative activities of doripenem versus isolates,mutants,and transconjugants of Enterobacteriaceae and Acinetobacter spp.with characterized β -lactamases[J].Antimicrob Agents Chemother,2004,48(4):1313-1319.
- [4]MARTI S,SANCHEZ-CESPEDES J,ALBA V,et al.In vitro activity of doripenem against Acinetobacter baumannii clinical isolates[J].Int J Antimicrob Agents,2009,33(2):181-182.
- [5]ZHANEL GG,WIEBE R,DILAY L,et al.Comparative review of the carbapenems[J].Drugs,2007,67(7):1027-1052.
- [6]HAMMAMI S,GHOZZI R,SAIDANI M,et al.Carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in Tunisia[J].Tunis Med,2011,89(7):638-643.
- [7]RUMBO C,FERNANDEZ-MOREIRA E,MERINO M,et al.Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles:a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii[J].Antimicrob Agents Chemother,2011,55(7):3084-3090.
- [8]PUMBWE L,GLASS D,WEXLER HM.Efflux pump overexpression in multiple-antibiotic-resistant

[扩展功能](#)[本文信息](#)[PDF\(472K\)](#)[参考文献](#)[服务与反馈](#)[引用本文](#)[本文关键词相](#)[关文章](#)[多立培南](#)[碳青霉烯类](#)[抗菌药](#)[药物治疗法](#)[本文作者相关](#)[文章](#)[陆人杰](#)[唐风雷](#)[王燕龙](#)[朱珊梅](#)[徐军英](#)[蒋星](#)[中国知网](#)[陆人杰](#)

- mutants of *Bacteroides fragilis*[J]. *Antimicrob Agents Chemother*,2006,50(9):3150-3153.
- [9] YANG FC, YAN JJ, HUNG KH, et al. Characterization ofertapenem-resistant enterobacter cloacae in a Taiwanese university hospital[J]. *J Clin Microbiol*,2012,50(2):223-226.
- [10] ANDERSON DL. Doripenem[J]. *Drugs Today(Barc)*,2006,42(6):399-404.
- [11] LISTER PD. Carbapenems in the USA: focus on doripenem[J]. *Expert Rev Anti Infect Ther*,2007,5(5):793-809.
- [12] BROWN SD, TRACZEWSKI MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control[J]. *J Antimicrob Chemother*,2005,55(6):944-949.
- [13] SAHM D. In vitro activity of doripenem[J]. *Clin Infect Dis*,2009,49 Suppl 1:S11-S16.
- [14] GELFAND MS, CLEVELAND KO, MAZUMDER SA. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant *Pseudomonas aeruginosa*[J]. *J Antimicrob Chemother*,2009,63(6):1297-1299.
- [15] FRITSCH TR, SADER HS, STILLWELL MG, et al. Antimicrobial activity of doripenem tested against prevalent gram-positive pathogens: results from a global surveillance study (2003-2007)[J]. *Diagn Microbiol Infect Dis*,2009,63(4):440-446.
- [16] JONES RN, BELL JM, SADER HS, et al. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens[J]. *Diagn Microbiol Infect Dis*,2009,63(4):434-439.
- [17] 唐红英, 刘江慧, 邹建军, 等. 高效液相色谱-串联质谱法测定人血浆中多尼培南的浓度[J]. *中国新药与临床杂志*,2009,28(5):380-384.
- [18] BURIAN B, ZEITLINGER M, DONATH O, et al. Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers[J]. *Antimicrob Agents Chemother*,2012,56(1):532-535.
- [19] PATERSON DL, DEPESTEL DD. Doripenem[J]. *Clin Infect Dis*,2009,49(2):291-298.
- [20] HORI T, NAKANO M, KIMURA Y, et al. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals[J]. *In vivo*,2006,20(1):91-96.
- [21] CRANDON JL, SUTHERLAND C, NICOLAU DP. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps[J]. *Am J Health Syst Pharm*,2010,67(18):1539-1544.
- [22] PSATHAS PA, KUZMISSION A, IKEDA K, et al. Stability of doripenem in vitro in representative infusion solutions and infusion bags[J]. *Clin Ther*,2008,30(11):2075-2087.
- [23] BRAMMER MK, CHAN P, HEATHERLY K, et al. Compatibility of doripenem with other drugs during simulated Y-site administration[J]. *Am J Health Syst Pharm*,2008,65(13):1261-1265.
- [24] RxList. Doribax (doripenem) product monograph [EB/OL]. (2012-02-16) [2012-10-08]. <http://www.rxlist.com/doribax-drug.htm>.
- [25] MORI H, TAKAHASHI K, MIZUTANI T. Interaction between valproic acid and carbapenem antibiotics[J]. *Drug Metab Rev*,2007,39(4):647-657.
- [26] MASUO Y, ITO K, YAMAMOTO T, et al. Characterization of inhibitory effect of carbapenem antibiotics on the deconjugation of valproic acid glucuronide[J]. *Drug Metab Dispos*,2010,38(10):1828-1835.
- [27] CADA D, LEVIEN T, MISTRY B, et al. Doripenem for injection[J]. *Hospital Pharmacy*,2008,43(2):210-218.
- [28] LUCASTI C, JASOVICH A, UMEH O, et al. Efficacy and tolerability of doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study[J]. *Clin Ther*,2008,30(5):868-883.
- [29] NABER KG, LLORENS L, KANIGA K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower

urinary tract infection and pyelonephritis[J]. *Antimicrob Agents Chemother*,2009,53(9):3782-3792.

[30] RA-NETO A, NIEDERMAN M, LOBO SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study[J]. *Curr Med Res Opin*,2008,24(7):2113-2126.

[31] KONGNAKORN T, MWAMBURI M, MERCHANT S, et al. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation[J]. *Curr Med Res Opin*,2010,26(1):17-24.

[32] CHASTRE J, WUNDERINK R, PROKOCIMER P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study[J]. *Crit Care Med*,2008,36(4):1089-1096.

[33] KOZIO-MONTEWKA M, JAWORSKA-GROMASZEK I, BIERNACKA J, et al. Review of the effectiveness of an empirical antibiotic therapy in suspected ventilator-associated pneumonia [J]. *Anestezjol Intens Ter*,2011,43(3):163-168.

[34] KOLLEF MH, NATHWANI D, MERCHANT S, et al. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators[J]. *Crit Care*,2010,14(3):R84.

[35] HORIUCHI M, KIMURA M, TOKUMURA M, et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics[J]. *Toxicology*,2006,222(1-2):114-124.

[36] REDMAN R, FILE TM Jr. Safety of intravenous infusion of doripenem[J]. *Clin Infect Dis*,2009,49 Suppl 1:S28-S35.

[37] SAWADA Y, SUGITA K, FUKAMACHI S, et al. Doripenem-induced intertriginous drug eruption as a mild form of AGEP[J]. *J Eur Acad Dermatol Venereol*,2009,23(8):974-976.
